Cui Yimin / Professor
Director of the Department of Pharmacy, Peking University First Hospital, Deputy Director of the Department of Pharmaceutical Management and Clinical Pharmacy
Doctoral Supervisor, Director of the Department of Pharmacy of Peking University First Hospital, Deputy Director of the Department of Pharmaceutical Affairs Management and Clinical Pharmacy, Peking University School of Pharmacy, Deputy Director of the Clinical Pharmacology Professional Committee of the Chinese Pharmacological Society, Chairman of the Chinese Pharmaceutical Clinical Trial Institutions Alliance, Chinese Pharmaceutical Association Member of the Hospital Pharmacy Professional Committee, member of the Pharmaceutical Management Professional Committee of the Chinese Hospital Association, and editorial board member of the Chinese Journal of New Drugs, the Chinese Journal of Clinical Pharmacology, and the Journal of Adverse Drug Reactions.
The chief scientist of the first phase of the registration of the national 1.5-type multi-effect fixed compound new drug "amlodipine folic acid tablets (ammonia leaves)". He is currently the director and doctoral supervisor of the Clinical Trial Center of Peking University First Hospital. The “Establishment of Pharmacogenomics Technology Platform for New Drug Clinical Trials” project won the second prize of the Science and Technology Award of the Chinese Pharmaceutical Association in 2012, the third prize of the China Medical Science and Technology Award in 2013, and was named the “Most Influential Chinese Pharmaceutical Innovation Brand Series” in 2017 Innovative People", won the WuXi AppTec Life Chemistry Research Scholarship Award in 2017, and won the Wu Jieping Paul Janssen Medical Pharmacy Award in 2018. Academic part-time jobs include the vice chairman of the Higher Education Pharmaceutical Education Steering Committee of the Ministry of Education, a member of the National Pharmacopoeia Committee, a member of the National Generic Drug Quality and Efficacy Consistency Evaluation Expert Committee, and a consultant of the National Drug Evaluation Center; the Chinese Pharmaceutical Association's industry-university-research and innovation work Deputy Chairman of the Committee; Deputy Secretary-General of the Chinese Pharmacological Society, and appointed chairman of the Clinical Pharmacology Professional Committee of the Chinese Pharmacological Society. The post-marketing clinical study of enalapril folic acid tablets, a major national major new drug creation project during the “Twelfth Five-Year Plan” period, a member of the steering committee of the "Chinese Stroke Primary Prevention Study (CSPPT)", won the 2013 China Pharmaceutical Development Special Contribution Award.